Eli Lilly and Companys in-depth data and chart pattern analysis indicates that the stock price has rallied 22.39% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 5.92% . Looking at the past 52 week period, the stock price is up at 12.6% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Eli Lilly and Company has a positive value of 2.14 compared to overall market.
Eli Lilly and Company stock has recorded a 20-day Moving Average of 6.37% and the 50-Day Moving Average is 9.91%.The 200 Day SMA reached 9.2%Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 80.89. Eli Lilly and Company (NYSE:LLY) has climbed 3.09% in the past week and advanced 9.94% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 2.38% and the outperformance has advanced to 6.56% for the last 4 weeks period.
Eli Lilly and Company (NYSE:LLY) : On Friday heightened volatility was witnessed in Eli Lilly and Company (NYSE:LLY) which led to swings in the share price. The stock opened for trading at $82.42 and hit $83.24 on the upside , eventually ending the session at $82.87, with a gain of 0.39% or 0.32 points. The heightened volatility saw the trading volume jump to 4,016,045 shares. The 52-week high of the share price is $83.785 and the company has a market cap of $91,435 million. The 52-week low of the share price is at $64.18 .
Currently the company Insiders own 0.2% of Eli Lilly and Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.54% . Institutional Investors own 74.46% of Eli Lilly and Company shares. During last six month period, the net percent change held by insiders has seen a change of -0.55%. Company has reported several Insider transactions to the SEC, on Feb 21, 2017, Endowment Inc Lilly (10% owner) sold 230,000 shares at 80.27 per share price.On Feb 8, 2017, Alfonso G Zulueta (SVP& Pres., Emerging Markets) sold 15,000 shares at 77.66 per share price.On Feb 3, 2017, Derica W Rice (EVP-Global Services and CFO) sold 11,162 shares at 77.22 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Eli Lilly and Co was Upgraded by Morgan Stanley to Overweight on Dec 16, 2016.
Eli Lilly and Co Last issued its quarterly earnings results on Jan 31, 2017. The company reported $0.95 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.98. The company had revenue of $5760.50 million for the quarter, compared to analysts expectations of $5554.54 million. The companys revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS.
Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.